<DOC>
	<DOCNO>NCT02407223</DOCNO>
	<brief_summary>The purpose study assess efficacy safety ustekinumab adult participant active nonradiographic axial spondyloarthritis ( nr-AxSpA ) measure reduction sign symptom nonradiographic axial spondyloarthritis ( nr-AxSpA ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Ustekinumab Participants With Active Nonradiographic Axial Spondyloarthritis</brief_title>
	<detailed_description>This phase 3 , multicenter , randomize , double-blind , placebo-controlled study evaluate efficacy safety ustekinumab treatment participant active non-radiographic axial spondylo arthritis . Participants receive either placebo ustekinumab 45 90 milligram ( mg ) . Participants primarily assess Assessment Spondylo Arthritis ( ASAS ) International Society criterion 20 Week 24 . Safety monitor throughout study .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<criteria>Participants must classify nonradiographic axial spondyloarthritis ( nrAxSpA ) base 2009 Assessment SpondyloArthritis International Society ( ASAS ) criterion Must age nrAxSpA onset &lt; = 45 year Must screen active inflammation magnetic resonance imaging ( MRI ) evidence central reader radiographic sacroiliitis fulfills 1984 modify New York Criteria Must symptom active disease screen baseline , evidence BASDAI score &gt; = 4 visual analogue scale ( VAS ) score total back pain equal ( &gt; = ) 4 , scale 0 10 Have radiographic sacroiliitis fulfilling 1984 modify New York Criteria Have inflammatory disease might confound evaluation benefit ustekinumab therapy Have receive systemic immunosuppressive diseasemodifying antirheumatic drug ( DMARDs ) methotrexate ( MTX ) , sulfasalazine ( SSZ ) , hydroxychloroquine ( HCQ ) within 4 week prior first administration study agent Have receive epidural , intraarticular , intramuscular ( IM ) , intravenous ( IV ) corticosteroid , include adrenocorticotropic hormone 4 week prior first administration study agent Have receive prior biologic therapy antiTNFα Have receive 1 prior antiTNFα agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Nonradiographic Axial Spondylitis , Ankylosing</keyword>
	<keyword>Ustekinumab</keyword>
</DOC>